Financial reports
ARS
2014 FY
Annual report to shareholders
28 Apr 15
10-K
2014 FY
Annual report
10 Dec 14
10-Q
2014 Q3
Quarterly report
7 Aug 14
10-Q
2014 Q2
Quarterly report
7 May 14
10-Q
2014 Q1
Quarterly report
6 Feb 14
10-K
2013 FY
Annual report
11 Dec 13
10-Q
2013 Q3
Quarterly report
8 Aug 13
10-Q
2013 Q2
Quarterly report
9 May 13
10-Q
2013 Q1
Quarterly report
8 Feb 13
10-K
2012 FY
Annual report
13 Dec 12
Current reports
8-K
Completion of Acquisition or Disposition of Assets
13 Jan 15
8-K
Avanir Pharmaceuticals to Be Acquired by Otsuka
2 Dec 14
8-K
Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA
28 Nov 14
8-K
Departure of Directors or Certain Officers
12 Nov 14
8-K
Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine
7 Nov 14
8-K
Entry into a Material Definitive Agreement
25 Sep 14
8-K
Avanir Pharmaceuticals Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer’s Disease
15 Sep 14
8-K
Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
5 Aug 14
8-K
Other Events
7 May 14
8-K
Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results
6 May 14
Registration and prospectus
15-12B
Securities registration termination
15 Jan 15
25-NSE
Exchange delisting
13 Jan 15
POS AM
Prospectus update (post-effective amendment)
13 Jan 15
POS AM
Prospectus update (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Jan 15
Proxies
DEFA14A
Additional proxy soliciting materials
10 Jan 14
DEF 14A
Definitive proxy
30 Dec 13
DEFA14A
Additional proxy soliciting materials
30 Dec 13
PRE 14A
Preliminary proxy
18 Dec 13
DEFA14A
Additional proxy soliciting materials
20 Dec 12
DEF 14A
Definitive proxy
20 Dec 12
DEFA14A
Additional proxy soliciting materials
21 Dec 11
DEF 14A
Definitive proxy
21 Dec 11
DEF 14A
Definitive proxy
23 Dec 10
DEFA14A
Additional proxy soliciting materials
23 Dec 10
Other
EFFECT
Notice of effectiveness
14 Jan 15
EFFECT
Notice of effectiveness
14 Jan 15
UPLOAD
Letter from SEC
22 Jul 14
CORRESP
Correspondence with SEC
17 Jul 14
CORRESP
Correspondence with SEC
27 Jun 14
CORRESP
Correspondence with SEC
23 Jun 14
CORRESP
Correspondence with SEC
16 May 14
CORRESP
Correspondence with SEC
8 May 14
CORRESP
Correspondence with SEC
23 Apr 14
UPLOAD
Letter from SEC
14 Apr 14
Ownership
SC 13G/A
Avanir Pharmaceuticals, Inc.
11 Feb 15
SC 13G/A
Avanir Pharmaceuticals, Inc.
10 Feb 15
SC 13G/A
Avanir Pharmaceuticals, Inc.
9 Feb 15
SC 13G/A
Avanir Pharmaceuticals, Inc.
26 Jan 15
SC 13G/A
Avanir Pharmaceuticals, Inc.
12 Jan 15
SC 13G/A
Beneficial ownership report (amended)
10 Nov 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
10 Nov 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
12 Sep 14
SC 13G
Avanir Pharmaceuticals, Inc.
10 Jun 14
SC 13G/A
Avanir Pharmaceuticals, Inc.
14 Feb 14